Seaport Therapeutics doses first patient in GlyphAgo anxiety trial

October 7, 2026 7:00 AM

Seaport Therapeutics (Nasdaq: SPTX) announced that the first patient has been dosed in a Phase 2a clinical trial in Australia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found